ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för upadacitinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

21 träffar

Bibliografisk träff 2024-02-09

Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.

Chen L, Tang Y, Lang JJ, Lin Y, Yu Z, Li X, Zheng X, Mi P, Lv Y, Lin YW.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2024.116210

Bibliografisk träff 2023-11-30

Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.

Park E, Park S, Lee SJ, Jeong D, Jin H, Moon H, Cha B, Kim D, Ma S, Seo W, Han SH, Lee YS, Kang S.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c01712

Bibliografisk träff 2023-09-29

Synthesis and clinical application of small-molecule inhibitors of Janus kinase.

Zhang JY, Sun JF, Nie P, Herdewijn P, Wang YT.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115848

Bibliografisk träff 2023-06-30

The Hitchhiker's Guide to Deep Learning Driven Generative Chemistry.

Ivanenkov Y, Zagribelnyy B, Malyshev A, Evteev S, Terentiev V, Kamya P, Bezrukov D, Aliper A, Ren F, Zhavoronkov A.

ACS Med Chem Lett · review-article; review; journal article · DOI 10.1021/acsmedchemlett.3c00041

Bibliografisk träff 2023-04-29

Clinically approved small-molecule drugs for the treatment of rheumatoid arthritis.

Zhao JH, Ma S, Li CY, Zhang HC, Zhao LJ, Zhang ZY.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115434

Bibliografisk träff 2023-04-14

Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.

Qiu Q, Chi F, Zhou D, Xie Z, Liu Y, Wu H, Yin Z, Shi W, Qian H.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c00036

Bibliografisk träff 2023-01-19

Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis.

Thoma G, Duthaler RO, Waelchli R, Hauchard A, Bruno S, Strittmatter-Keller U, Orjuela Leon A, Viebrock S, Aichholz R, Beltz K, Grove K, Hoque S, Rudewicz PJ, Zerwes HG.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.2c01977

Bibliografisk träff 2022-09-02

Discovery of Novel Imidazo[4,5-c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis.

Liang X, Xie Y, Liu X, Xu H, Ren H, Tang S, Liu Q, Huang M, Shao X, Li C, Zhou Y, Geng M, Xie Z, Liu H.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c00390

Bibliografisk träff 2022-06-18

Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.

Shen P, Wang Y, Jia X, Xu P, Qin L, Feng X, Li Z, Qiu Z.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114551

Bibliografisk träff 2021-11-11

Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors.

Kim W, Lee SM, Jeong PH, Jung JH, Kim YC.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2021.128451

Bibliografisk träff 2021-05-18

Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches.

Hall A, Chanteux H, Ménochet K, Ledecq M, Schulze MED.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.0c02245

Bibliografisk träff 2021-02-04

Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.

Raghuvanshi R, Bharate SB.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.0c01467

Bibliografisk träff 2020-08-31

Cyclic tailor-made amino acids in the design of modern pharmaceuticals.

Liu J, Han J, Izawa K, Sato T, White S, Meanwell NA, Soloshonok VA.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112736

Bibliografisk träff 2019-07-18

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.

Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L, Shuster D, Gillooly K, Yang X, Heimrich E, McIntyre KW, Chaudhry C, Khan J, Ruzanov M, Tredup J, Mulligan D, Xie D, Sun H, Huang C, D'Arienzo C, Aranibar N, Chiney M, Chimalakonda A, Pitts WJ, Lombardo L, Carter PH, Burke JR, Weinstein DS.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.9b00444

Bibliografisk träff 2019-06-25

Small-molecule agents for the treatment of inflammatory bowel disease.

Currie KS, Patel L, Sedillo KF.

Bioorg Med Chem Lett · review; journal article · DOI 10.1016/j.bmcl.2019.06.042

Bibliografisk träff 2019-04-04

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.

Zak M, Hanan EJ, Lupardus P, Brown DG, Robinson C, Siu M, Lyssikatos JP, Romero FA, Zhao G, Kellar T, Mendonca R, Ray NC, Goodacre SC, Crackett PH, McLean N, Hurley CA, Yuen PW, Cheng YX, Liu X, Liimatta M, Kohli PB, Nonomiya J, Salmon G, Buckley G, Lloyd J, Gibbons P, Ghilardi N, Kenny JR, Johnson A.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2019.04.008

Bibliografisk träff 2019-03-25

Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.

Wang Y, Huang W, Xin M, Chen P, Gui L, Zhao X, Zhu X, Luo H, Cong X, Wang J, Liu F.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.03.048

Bibliografisk träff 2018-08-28

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).

Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, Rosebraugh M, Wishart N, Olson L, Long AJ.

BMC Rheumatol · research-article; journal article · DOI 10.1186/s41927-018-0031-x

Bibliografisk träff 2018-06-15

Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.

Bryan MC, Rajapaksa NS.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.8b00667

Bibliografisk träff 2018-01-15

Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.

Chough C, Lee S, Joung M, Lee J, Kim JH, Kim BM.

Medchemcomm · research-article; journal article · DOI 10.1039/c7md00568g

Bibliografisk träff 2015-09-01

Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.

Kim MK, Shin H, Park KS, Kim H, Park J, Kim K, Nam J, Choo H, Chong Y.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.5b01263

Gå till forskningen.

Publikationer i urvalet

Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.

Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.

Synthesis and clinical application of small-molecule inhibitors of Janus kinase.

The Hitchhiker's Guide to Deep Learning Driven Generative Chemistry.

Clinically approved small-molecule drugs for the treatment of rheumatoid arthritis.

Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.

Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis.

Discovery of Novel Imidazo[4,5-<i>c</i>]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis.

Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.

Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors.

Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches.

Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.

Cyclic tailor-made amino acids in the design of modern pharmaceuticals.

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.

Small-molecule agents for the treatment of inflammatory bowel disease.

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.

Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).

Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.

Design, synthesis and evaluation of (<i>R</i>)-3-(7-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.

Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.